By Michael Dabaie

 

Pfizer Inc. (PFE) said results were positive from a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis.

Patients who achieved low disease activity with Xeljanz extended release 11 mg once daily plus methotrexate after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of Xeljanz as monotherapy. The study demonstrated non-inferiority of methotrexate withdrawal with Xeljanz at week 48, Pfizer said.

The study results will be presented during a late-breaking oral session at the Annual European Congress of Rheumatology in Madrid on June 15.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 12, 2019 08:43 ET (12:43 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Pfizer
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Pfizer